Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:phylloquinone
go back to main search page
Accession:CHEBI:18067 term browser browse the term
Definition:A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.
Synonyms:related_synonym: 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione;   2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone;   2-Methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dione;   2-Methyl-3-phytyl-1,4-naphthochinon;   2-Methyl-3-phytyl-1,4-naphthoquinone;   3-Phytylmenadione;   Formula=C31H46O2;   InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1;   InChIKey=MBWXNTAXLNYFJB-NKFFZRIASA-N;   Phyllochinon;   Phyllochinonum;   Phytomenadione;   Phytonadione;   Phytonadionum;   Phytylmenadione;   SMILES=CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\\C(C)=C\\CC1=C(C)C(=O)c2ccccc2C1=O;   Vitamin K1;   alpha-phylloquinone;   fitomenadiona;   phytomenadionum;   trans-Phylloquinone
 alt_id: CHEBI:11611;   CHEBI:14833;   CHEBI:26105;   CHEBI:45148;   CHEBI:8181
 xref: CAS:84-80-0;   DrugBank:DB01022;   Drug_Central:2843;   HMDB:HMDB0003555;   KEGG:C02059;   KEGG:D00148;   KNApSAcK:C00002868
 xref_mesh: MESH:D010837
 xref: PDBeChem:PQN;   PMID:11003724;   PMID:15686525;   PMID:19588895;   PMID:19996170;   PMID:21169510;   PMID:21645693;   PMID:21844348;   PMID:21914559;   Reaxys:2568816;   Wikipedia:Phytonadione


show annotations for term's descendants           Sort by:
 
phylloquinone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP [Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein] CTD PMID:27212383 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Axl Axl receptor tyrosine kinase multiple interactions EXP [Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein] CTD PMID:27212383 NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO
EXP
[sorafenib co-treated with Vitamin K 1] results in decreased expression of BCL2 protein
[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein]
CTD PMID:20301194, PMID:27212383 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bglap bone gamma-carboxyglutamate protein increases carboxylation
multiple interactions
ISO Vitamin K 1 results in increased carboxylation of BGLAP protein
Warfarin inhibits the reaction [Vitamin K 1 results in increased carboxylation of BGLAP protein]
CTD PMID:31173816 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased cleavage of BID protein CTD PMID:20301194 NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
JBrowse link
G Bmp2 bone morphogenetic protein 2 multiple interactions EXP [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein] CTD PMID:27412937 NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein
[Warfarin co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein
CTD PMID:20301194, PMID:23990204 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased cleavage of CASP8 protein CTD PMID:20301194 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G F2 coagulation factor II increases expression ISO Vitamin K 1 deficiency results in increased expression of F2 protein modified form CTD PMID:2821104 NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
JBrowse link
G F9 coagulation factor IX multiple interactions ISO [VKORC1 protein results in increased reduction of Vitamin K 1] which results in increased carboxylation of and results in increased activity of F9 protein; [VKORC1L1 protein results in increased reduction of Vitamin K 1] which results in increased carboxylation of and results in increased activity of F9 protein CTD PMID:29581108 NCBI chr  X:143,097,507...143,141,791
Ensembl chr  X:143,097,525...143,141,794
JBrowse link
G Faslg Fas ligand multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased expression of FASLG protein] CTD PMID:20301194 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit increases expression ISO Vitamin K 1 results in increased expression of FOS mRNA CTD PMID:19273458 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gas6 growth arrest specific 6 multiple interactions EXP [Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein; Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein] CTD PMID:27212383 NCBI chr16:81,213,364...81,243,824
Ensembl chr16:81,213,364...81,243,757
JBrowse link
G Gstp1 glutathione S-transferase pi 1 multiple interactions ISO Vitamin K 1 inhibits the reaction [GSTP1 protein results in increased metabolism of 1-chloro-2,4-dinitrobenzene-glutathione conjugate] CTD PMID:23769903 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G Il6 interleukin 6 multiple interactions EXP Vitamin K 1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] CTD PMID:16636460 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [[sorafenib co-treated with Vitamin K 1] results in increased phosphorylation of JUN protein] CTD PMID:20301194 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK1 protein CTD PMID:20301194 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO [sorafenib co-treated with Vitamin K 1] results in decreased phosphorylation of MAPK3 protein CTD PMID:20301194 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mgp matrix Gla protein multiple interactions EXP
ISO
Vitamin K 1 results in increased expression of and results in increased secretion of MGP protein modified form; Warfarin inhibits the reaction [Vitamin K 1 results in increased expression of and results in increased secretion of MGP protein modified form]
[[Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein] which results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased activity of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein; [Warfarin co-treated with Vitamin K 1] results in decreased expression of MGP mRNA
CTD PMID:21705322, PMID:23990204 NCBI chr 4:170,856,783...170,860,105
Ensembl chr 4:170,856,751...170,860,225
JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions EXP [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA; [Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein] CTD PMID:27412937 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions ISO [Warfarin co-treated with Vitamin K 1] results in increased expression of SPP1 mRNA CTD PMID:23990204 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Tagln transgelin multiple interactions ISO [Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA CTD PMID:23990204 NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
JBrowse link
G Vkorc1 vitamin K epoxide reductase complex, subunit 1 multiple interactions
increases reduction
ISO 4-hydroxycoumarin inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; [VKORC1 protein results in increased reduction of Vitamin K 1] which results in increased carboxylation of and results in increased activity of F9 protein; Acenocoumarol inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; bromadiolone inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; bromfenacoum inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; coumachlor inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; coumatetralyl inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; Dicumarol inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; ferulenol inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; Phenindione inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; Phenprocoumon inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1 protein results in increased reduction of Vitamin K 1] CTD PMID:29581108 NCBI chr 1:199,338,785...199,341,306
Ensembl chr 1:199,337,138...199,341,302
JBrowse link
G Vkorc1l1 vitamin K epoxide reductase complex, subunit 1-like 1 multiple interactions
increases reduction
ISO 4-hydroxycoumarin inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; [VKORC1L1 protein results in increased reduction of Vitamin K 1] which results in increased carboxylation of and results in increased activity of F9 protein; Acenocoumarol inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; bromadiolone inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; bromfenacoum inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; coumachlor inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; coumatetralyl inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; Dicumarol inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; ferulenol inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; fluindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; Phenindione inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; Phenprocoumon inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1]; Warfarin inhibits the reaction [VKORC1L1 protein results in increased reduction of Vitamin K 1] CTD PMID:29581108 NCBI chr12:30,218,825...30,268,990
Ensembl chr12:30,222,701...30,268,990
JBrowse link
vitamin K term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acta2 actin alpha 2, smooth muscle multiple interactions EXP [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of ACTA2 mRNA CTD PMID:23117658 NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
JBrowse link
G Apoe apolipoprotein E affects abundance
affects uptake
ISO APOE protein affects the abundance of Vitamin K
APOE protein affects the uptake of Vitamin K
CTD PMID:15952022, PMID:16847429 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
JBrowse link
G Axin2 axin 2 multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA] CTD PMID:23117658 NCBI chr10:97,212,483...97,238,824
Ensembl chr10:97,212,432...97,239,642
JBrowse link
G Axl Axl receptor tyrosine kinase multiple interactions
increases expression
ISO Vitamin K inhibits the reaction [Warfarin results in decreased expression of AXL protein modified form]
Vitamin K results in increased expression of AXL protein modified form
CTD PMID:26206560 NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
JBrowse link
G Bglap bone gamma-carboxyglutamate protein multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA] CTD PMID:23117658 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Ccnd1 cyclin D1 multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA] CTD PMID:23117658 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cnn1 calponin 1 multiple interactions EXP [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of CNN1 mRNA CTD PMID:23117658 NCBI chr 8:23,113,083...23,121,748
Ensembl chr 8:23,113,048...23,121,761
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA] CTD PMID:23117658 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 multiple interactions
affects expression
decreases expression
EXP Lipopolysaccharides promotes the reaction [Vitamin K deficiency results in decreased expression of CYP11A1 mRNA]; Lipopolysaccharides promotes the reaction [Vitamin K deficiency results in decreased expression of CYP11A1 protein]
Vitamin K affects the expression of CYP11A1 mRNA
Vitamin K deficiency results in decreased expression of CYP11A1 mRNA; Vitamin K deficiency results in decreased expression of CYP11A1 protein
CTD PMID:16844298, PMID:21894328 NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
JBrowse link
G Fgg fibrinogen gamma chain affects expression EXP Vitamin K affects the expression of FGG mRNA CTD PMID:16636460 NCBI chr 2:181,987,080...181,994,523
Ensembl chr 2:181,987,217...181,994,514
JBrowse link
G Fnta farnesyltransferase, CAAX box, alpha affects expression EXP Vitamin K affects the expression of FNTA mRNA CTD PMID:16844298 NCBI chr16:70,834,957...70,854,724
Ensembl chr16:70,834,957...70,854,724
JBrowse link
G Gas6 growth arrest specific 6 affects carboxylation EXP Vitamin K affects the carboxylation of GAS6 protein CTD PMID:9163328 NCBI chr16:81,213,364...81,243,824
Ensembl chr16:81,213,364...81,243,757
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein] CTD PMID:23117658 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of IL1B mRNA CTD PMID:23117658 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il6 interleukin 6 multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of IL6 mRNA CTD PMID:23117658 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Lss lanosterol synthase affects expression EXP Vitamin K affects the expression of LSS mRNA CTD PMID:16844298 NCBI chr20:12,844,522...12,870,474
Ensembl chr20:12,842,884...12,870,497
JBrowse link
G Mgp matrix Gla protein multiple interactions EXP [Vitamin K co-treated with Warfarin] results in increased carboxylation of MGP protein CTD PMID:23223575 NCBI chr 4:170,856,783...170,860,105
Ensembl chr 4:170,856,751...170,860,225
JBrowse link
G Mvd mevalonate diphosphate decarboxylase affects expression EXP Vitamin K affects the expression of MVD mRNA CTD PMID:16844298 NCBI chr19:55,258,910...55,268,933
Ensembl chr19:55,258,905...55,268,951
JBrowse link
G Myh1 myosin heavy chain 1 multiple interactions EXP [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of MYH1 mRNA CTD PMID:23117658 NCBI chr10:53,740,841...53,764,610
Ensembl chr10:53,713,938...53,848,347
JBrowse link
G Numb NUMB, endocytic adaptor protein multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA] CTD PMID:23117658 NCBI chr 6:107,279,917...107,325,345
Ensembl chr 6:107,279,920...107,325,345
JBrowse link
G Orm1 orosomucoid 1 affects expression EXP Vitamin K affects the expression of ORM1 mRNA CTD PMID:16636460 NCBI chr 5:79,179,668...79,182,820
Ensembl chr 5:79,179,417...79,182,820
JBrowse link
G Pros1 protein S multiple interactions ISO Vitamin K affects the carboxylation of and affects the secretion of PROS1 protein CTD PMID:10706868 NCBI chr 7:1,206,648...1,288,140
Ensembl chr 7:1,206,648...1,288,134
JBrowse link
G Pth parathyroid hormone increases activity ISO Vitamin K results in increased activity of PTH protein CTD PMID:11564701 NCBI chr 1:178,215,829...178,218,761
Ensembl chr 1:178,215,829...178,218,761
JBrowse link
G Rabggta Rab geranylgeranyltransferase subunit alpha affects expression EXP Vitamin K affects the expression of RABGGTA mRNA CTD PMID:16844298 NCBI chr15:34,393,419...34,400,466
Ensembl chr15:34,393,233...34,400,449
JBrowse link
G Rabggtb Rab geranylgeranyltransferase subunit beta affects expression EXP Vitamin K affects the expression of RABGGTB mRNA CTD PMID:16844298 NCBI chr 2:260,110,309...260,115,574
Ensembl chr 2:260,110,309...260,115,577
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP Vitamin K deficiency promotes the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] CTD PMID:21894328 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rrad RRAD, Ras related glycolysis inhibitor and calcium channel regulator affects expression EXP Vitamin K affects the expression of RRAD mRNA CTD PMID:16844298 NCBI chr19:561,696...564,929
Ensembl chr19:561,727...564,930
JBrowse link
G Runx2 RUNX family transcription factor 2 multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA] CTD PMID:23117658 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of SPP1 mRNA CTD PMID:23117658 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Tagln transgelin multiple interactions EXP [Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA CTD PMID:23117658 NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
JBrowse link
G Tcf4 transcription factor 4 multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA] CTD PMID:23117658 NCBI chr18:65,285,320...65,507,983
Ensembl chr18:65,155,685...65,507,977
JBrowse link
G Tgm2 transglutaminase 2 multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein; Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein] CTD PMID:23117658 NCBI chr 3:154,597,165...154,627,257
Ensembl chr 3:154,597,168...154,627,257
JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [Warfarin co-treated with Vitamin K] results in increased expression of TNF mRNA CTD PMID:23117658 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Ubiad1 UbiA prenyltransferase domain containing 1 increases metabolic processing
multiple interactions
ISO UBIAD1 protein results in increased metabolism of Vitamin K metabolite
[UBIAD1 protein results in increased metabolism of Vitamin K metabolite] which results in increased chemical synthesis of menatetrenone
CTD PMID:20953171 NCBI chr 5:165,247,630...165,259,228
Ensembl chr 5:165,247,133...165,259,224
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    role 19732
      biological role 19732
        biochemical role 19281
          cofactor 15529
            phylloquinone 50
              vitamin K + 34
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic group 18493
                              organic divalent group 18486
                                organodiyl group 18486
                                  carbonyl group 18389
                                    carbonyl compound 18389
                                      ketone 16140
                                        cyclic ketone 13810
                                          quinone 8336
                                            naphthoquinone 1428
                                              phytylnaphthoquinone 50
                                                phylloquinones 50
                                                  phylloquinone 50
                                                    vitamin K + 34
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.